Canoe Financial LP Buys 148,999 Shares of Thermo Fisher Scientific Inc. $TMO

Canoe Financial LP grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 92.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 309,994 shares of the medical research company’s stock after purchasing an additional 148,999 shares during the quarter. Thermo Fisher Scientific comprises about 1.9% of Canoe Financial LP’s portfolio, making the stock its 20th biggest holding. Canoe Financial LP owned about 0.08% of Thermo Fisher Scientific worth $155,419,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of TMO. Legacy Wealth Managment LLC ID raised its stake in Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after purchasing an additional 22 shares in the last quarter. Allied Private Wealth LLC bought a new stake in shares of Thermo Fisher Scientific in the second quarter worth $26,000. High Note Wealth LLC raised its position in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after purchasing an additional 29 shares during the last quarter. Swiss RE Ltd. acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $28,000. Finally, JPL Wealth Management LLC bought a new position in Thermo Fisher Scientific during the third quarter worth $28,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Ratings Changes

TMO has been the topic of several research reports. KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Barclays boosted their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Robert W. Baird dropped their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Finally, Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.

Thermo Fisher Scientific Stock Down 1.3%

TMO opened at $588.17 on Friday. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The firm has a 50-day simple moving average of $529.37 and a two-hundred day simple moving average of $509.58. The company has a market capitalization of $217.48 billion, a PE ratio of 31.64, a price-to-earnings-growth ratio of 2.42 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same period in the prior year, the firm earned $4.28 EPS. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the sale, the chief operating officer owned 24,651 shares in the company, valued at $13,927,815. This represents a 1.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $574.47, for a total transaction of $5,744,700.00. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at $71,191,194.75. This represents a 7.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 52,053 shares of company stock worth $30,643,589. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.